Tarsheen Sethi, MD, MSc

• Amer Zeidan
• Francesca Montanari
• Francine Foss
• Lohith Gowda
• Mina Xu
• Nikolai Podoltsev
• Noffar Bar
• Ronald George Hauser
• Rong Wang
• Savanah Gisriel
• Scott Huntington
• Shalin Kothari
• Stuart Seropian
• Xiaomei Ma

Hodgkin Disease; Lymphoma

• Investigating the impact of demographic disparities on clinical outcomes in cutaneous T-cell lymphoma (CTCL): A multicenter retrospective cohort analysis.Niyogusaba T, Switchenko J, Rozati S, Iyer S, Talluru S, Huen A, Greenwell I, Scribner J, Rangarajan S, Mehta A, Beaven A, Bhatti S, Krishanasamy S, Porcu P, Sethi T, Foss F, Paulino D, Case K, Lechowicz M, Allen P. Investigating the impact of demographic disparities on clinical outcomes in cutaneous T-cell lymphoma (CTCL): A multicenter retrospective cohort analysis. Journal Of Clinical Oncology 2023, 41: 7573-7573. DOI: 10.1200/jco.2023.41.16_suppl.7573.
• 523 Allogeneic Transplantation for Rare Subtypes of T-Cell Lymphoma: Outcomes with a Pentostatin/Low-Dose Total Body Irradiation RegimenDi M, Mirza A, Hamouche R, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 523 Allogeneic Transplantation for Rare Subtypes of T-Cell Lymphoma: Outcomes with a Pentostatin/Low-Dose Total Body Irradiation Regimen. Transplantation And Cellular Therapy 2023, 29: s392. DOI: 10.1016/s2666-6367(23)00591-2.
• 517 Outcomes after Reduced-Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with T Cell Prolymphocytic Leukemia (T-PLL): A Single Institution ExperienceHamouche R, Mirza A, Di M, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. 517 Outcomes after Reduced-Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with T Cell Prolymphocytic Leukemia (T-PLL): A Single Institution Experience. Transplantation And Cellular Therapy 2023, 29: s387-s388. DOI: 10.1016/s2666-6367(23)00585-7.
• Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysisDi M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.
• Primary Cutaneous Lymphomas Perez & Brady's Principles and Practice of Radiation Oncology (8th edition). In Press.
• Sethi TK, Kothari S , Mulvey E, Foss F, Leonard J, Greer J. Non-Hodgkin Lymphoma in AdultsMeans, Robert T.(2023). Wintrobe's Clinical Hematology (15th Edition). Lippincott Williams & Wilkins (LWW).
• Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical CentersAllen P, Goyal S, Iyer S, Talluru S, Huen A, Greenwell I, Scribner J, Speegle S, Niyogusaba T, Rangarajan S, Mehta A, O'Leary C, Beaven A, Switchenko J, Ayers A, Bhatti S, Krishnasamy S, Porcu P, Sethi T, Foss F, Lechowicz M, Rozati S. Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers. Blood 2022, 140: 9431-9433. DOI: 10.1182/blood-2022-170921.
• Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based AnalysisDi M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Stempel J, Ma X, Huntington S. Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis. Blood 2022, 140: 10904-10906. DOI: 10.1182/blood-2022-164959.
• A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virusDittus C, Grover N, Sethi T, Cohen JB, Voloschin A, Rabadey J, Tan X, Beaven A, Park SI. A multicenter, real‐world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus. EJHaem 2022, 3: 734-738. PMID: 36051081, PMCID: PMC9421958, DOI: 10.1002/jha2.474.
• Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses.Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses. Journal Of Clinical Oncology 2022, 40: 7554-7554. DOI: 10.1200/jco.2022.40.16_suppl.7554.
• Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristicsGisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.
• Safety considerations with the current treatments for peripheral T-cell lymphomaSethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.
• Foss F , Sethi T , Girardi M, Wilson, L. Cutaneous Lymphomas DeVita, Hellman, and Rosenberg's Cancer Principles & Practice of Oncology( 2022,12th edition). Lippincott Williams & Wilkins (LWW).
• Chemotherapy Knowledge Base Management in the Era of Precision Oncology.Rubinstein SM, Sethi T, Venepalli NK, Gyawali B, Schwartz C, Rivera DR, Yang PC, Warner JL. Chemotherapy Knowledge Base Management in the Era of Precision Oncology. JCO Clinical Cancer Informatics 2021, 5: 30-35. PMID: 33411619, PMCID: PMC8189622, DOI: 10.1200/cci.20.00076.
• No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective AnalysisAllen P, Goyal S, Greenwell I, Scribner J, Rangarajan S, Mehta A, O'Leary C, Niyogusaba T, Huen A, Switchenko J, Tarabadkar E, Ayers A, Krishnasamy S, Porcu P, Sethi T, Iyer S, Lechowicz M. No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis. Blood 2021, 138: 2441. DOI: 10.1182/blood-2021-151911.
• EPOCH Is a Safe and Effective Treatment Option for Aggressive T-Cell LymphomasSethi T, Gerstein R, Schiffer M, Amin K, Agarwal S, Foss F. EPOCH Is a Safe and Effective Treatment Option for Aggressive T-Cell Lymphomas. Blood 2021, 138: 4547. DOI: 10.1182/blood-2021-151238.
• Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell TherapyHill B, Roth C, Kositsky R, Dave T, Love C, McKinney M, Galal A, Neff J, Mian A, Kendall E, Ondrejka S, Chiaramonte M, Bhagat G, Ofori K, Reshef R, Kovach A, Sethi T, Mason E, Bhaskar S, Oluwole O, Pallas C, Ghosh N, Ferdman R, Chen G, Hernandez-Ilizaliturri F, Zurko J, Cunningham A, Shah N, Hu B, Stephens D, Ghosh M, Bailey N, Patel K, Pagel J, Kannan K, Hsi E, Vaidya R, Ip A, Goy A, Kambhampati S, Ohgami R, Andreadis C, Thacker E, Rozzi C, Parker C, Happ L, Dave S. Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood 2021, 138: 165. DOI: 10.1182/blood-2021-145764.
• A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency VirusDittus C, Grover N, Sethi T, Cohen J, Voloschin A, Rabadey J, Tan X, Beaven A, Park S. A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus. Blood 2021, 138: 1457. DOI: 10.1182/blood-2021-145133.
• Primary sinonasal large B cell lymphoma is as histopathologically heterogeneous as systemic large B cell lymphoma but may show subtype-specific tropism for specific sinonasal anatomic sitesDesai M, Sethi T, Yenamandra A, Morgan D, Thompson M, Reddy N, Kovach A. Primary sinonasal large B cell lymphoma is as histopathologically heterogeneous as systemic large B cell lymphoma but may show subtype-specific tropism for specific sinonasal anatomic sites. Journal Of Hematopathology 2021, 14: 269-275. DOI: 10.1007/s12308-021-00473-5.
• How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndromeSethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.
• Breakthrough concepts in immune-oncology: Cancer vaccines at the bedsideRoy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal Of Leukocyte Biology 2020, 108: 1455-1489. PMID: 32557857, DOI: 10.1002/jlb.5bt0420-585rr.
• Trends in FDA cancer registration trial design over time, 1969-2020.Warner J, Sethi T, Rivera D, Venepalli N, Osterman T, Khaki A, Rubinstein S. Trends in FDA cancer registration trial design over time, 1969-2020. Journal Of Clinical Oncology 2020, 38: 2060-2060. DOI: 10.1200/jco.2020.38.15_suppl.2060.
• Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation CohortSethi T, Kovach A, Mason E, Chen H, Moyo T, Oluwole O, Morgan D, Reddy N. Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort. Blood 2019, 134: 4100. DOI: 10.1182/blood-2019-129634.
• Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment FailureEpperla N, Costa L, Vaughn J, Hanel W, Raya S, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta S, Caimi P, Sethi T, Reddy N, Burkart M, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery L, Lansigan F, Glenn M, Churnetski M, Cohen J, Sorge C, Xavier A. Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. Blood 2019, 134: 1554. DOI: 10.1182/blood-2019-129199.
• Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphomaSethi TK, Kovach AE, Grover NS, Huang LC, Lee LA, Rubinstein SM, Wang Y, Morgan DS, Greer JP, Park SI, Thompson-Arildsen M, Yenamandra A, Vnencak-Jones CL, Reddy NM. Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. Leukemia & Lymphoma 2019, 60: 2880-2889. PMID: 31184237, PMCID: PMC7280020, DOI: 10.1080/10428194.2019.1620942.
• Sethi TK, Morgan D. Hodgkin Lymphoma. J.P. Greer. (2019). Wintrobe’s Clinical Hematology (14th edition). Lippincott Williams & Wilkins (LWW).
• Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical TranslationAghighi M, Theruvath AJ, Pareek A, Pisani LL, Alford R, Muehe AM, Sethi TK, Holdsworth SJ, Hazard FK, Gratzinger D, Luna-Fineman S, Advani R, Spunt SL, Daldrup-Link HE. Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. Clinical Cancer Research 2018, 24: 4110-4118. PMID: 29764855, PMCID: PMC6125171, DOI: 10.1158/1078-0432.ccr-18-0673.
• Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapiesSethi TK, Reddy NM. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leukemia & Lymphoma 2018, 60: 6-18. PMID: 29741421, DOI: 10.1080/10428194.2018.1466296.
• Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain AmyloidosisOke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, Lenihan D, Rawling KT, Slosky D, Cornell RF. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. Transplantation And Cellular Therapy 2017, 23: 1473-1477. PMID: 28546074, DOI: 10.1016/j.bbmt.2017.05.020.
• Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic MalignanciesSethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Current Hematologic Malignancy Reports 2017, 12: 257-267. PMID: 28233150, DOI: 10.1007/s11899-017-0369-y.
• Current and Emerging Drug Therapies in Chronic Lymphocytic LeukemiaSethi T, Reddy N. Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia. TouchREVIEWS In Oncology & Haematology 2017, 13: 34. DOI: 10.17925/ohr.2017.13.01.34.
• Correlation of Toll-like Receptor (TLR) and PD-1 Pathways in Central Nervous System Lymphoma: A Clinicopathological Study on OutcomesSethi T, Kovach A, Rubinstein S, Lee L, Wang Y, Morgan D, Greer J, Vnencak-Jones C, Reddy N. Correlation of Toll-like Receptor (TLR) and PD-1 Pathways in Central Nervous System Lymphoma: A Clinicopathological Study on Outcomes. Blood 2016, 128: 929. DOI: 10.1182/blood.v128.22.929.929.
• Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphomaSethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Therapeutic Advances In Hematology 2016, 8: 13-20. PMID: 28042455, PMCID: PMC5167078, DOI: 10.1177/2040620716676256.
• Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HLSethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Clinical Lymphoma Myeloma & Leukemia 2016, 16: s68-s69. DOI: 10.1016/j.clml.2016.07.100.
• Beyond Epstein-Barr virus: genetic predisposition of natural killer T-cell lymphomaReddy NM, Sethi TK. Beyond Epstein-Barr virus: genetic predisposition of natural killer T-cell lymphoma. The Lancet Oncology 2016, 17: 1176-1177. PMID: 27470080, DOI: 10.1016/s1470-2045(16)30205-4.
• Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.Aghighi M, Boe J, Rosenberg J, Von Eyben R, Gawande RS, Petit P, Sethi TK, Sharib J, Marina NM, DuBois SG, Daldrup-Link HE. Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. Radiology 2016, 280: 905-15. PMID: 26982677, PMCID: PMC5006736, DOI: 10.1148/radiol.2016151301.
• Autologous Hematopoietic Cell Transplant (AHCT) Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis (AL) Compared with Chemotherapy AloneUkaegbu O, Sethi T, Goodman S, Rubinstein S, Hung R, Jagasia M, Kassim A, Lacy S, Langone A, Lenihan D, Savani B, Slosky D, Cornell R. Autologous Hematopoietic Cell Transplant (AHCT) Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis (AL) Compared with Chemotherapy Alone. Transplantation And Cellular Therapy 2016, 22: s233-s234. DOI: 10.1016/j.bbmt.2015.11.642.
• Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor SarcomasSethi TK, Keedy VL. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas. Current Treatment Options In Oncology 2016, 17: 11. PMID: 26931561, DOI: 10.1007/s11864-015-0382-0.
• Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple MyelomaChen J, Lenihan D, Phillips S, Jagasia M, Goodman S, Kassim A, Lacy S, McDonagh K, Moslehi J, Sethi T, Slosky D, Ukaegbu O, Cornell R. Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma. Blood 2015, 126: 5363. DOI: 10.1182/blood.v126.23.5363.5363.
• Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin LymphomaSethi T, Nguyen V, Morgan D, Greer J, Reddy N. Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma. Blood 2015, 126: 2640. DOI: 10.1182/blood.v126.23.2640.2640.
• Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL AmyloidosisDecker I, Ukaegbu O, Goodman S, Lenihan D, Hung R, Kassim A, Harrell S, McDonagh K, Phillips S, Rawling K, Rubinstein S, Sethi T, Cornell R. Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis. Blood 2015, 126: 1841. DOI: 10.1182/blood.v126.23.1841.1841.
• Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HLSethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Blood 2015, 126: 1441. DOI: 10.1182/blood.v126.23.1441.1441.
• Ibrutinib in chronic lymphocytic leukemiaReddy N, Sethi T. Ibrutinib in chronic lymphocytic leukemia. International Journal Of Hematologic Oncology 2015, 4: 143-150. DOI: 10.2217/ijh.15.15.
• Multicentric Castleman Disease with Complete Duodenal Obstruction in an HIV PatientSethi T, Alireza A, Kloecker G, Slone S. Multicentric Castleman Disease with Complete Duodenal Obstruction in an HIV Patient. Blood 2012, 120: 4834. DOI: 10.1182/blood.v120.21.4834.4834.
• Radon and lung cancer.Sethi TK, El-Ghamry MN, Kloecker GH. Radon and lung cancer. Clinical Advances In Hematology And Oncology 2012, 10: 157-64. PMID: 22402423.
• Iron deficiency masquerading as idiopathic intracranial hypertensionKaul B, Sivaramakrishnan R, Mahapatra H, Sethi TK, Ahlawat R. Iron deficiency masquerading as idiopathic intracranial hypertension. BMJ Case Reports 2009, 2009: bcr0620080346. PMID: 21686848, PMCID: PMC3028304, DOI: 10.1136/bcr.06.2008.0346.